1086 related articles for article (PubMed ID: 29301958)
21. Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.
Jazirehi AR; Baritaki S; Koya RC; Bonavida B; Economou JS
Cancer Res; 2011 Feb; 71(4):1406-17. PubMed ID: 21159666
[TBL] [Abstract][Full Text] [Related]
22. Altered BAF occupancy and transcription factor dynamics in PBAF-deficient melanoma.
Carcamo S; Nguyen CB; Grossi E; Filipescu D; Alpsoy A; Dhiman A; Sun D; Narang S; Imig J; Martin TC; Parsons R; Aifantis I; Tsirigos A; Aguirre-Ghiso JA; Dykhuizen EC; Hasson D; Bernstein E
Cell Rep; 2022 Apr; 39(1):110637. PubMed ID: 35385731
[TBL] [Abstract][Full Text] [Related]
23. Loss of PBRM1 Alters Promoter Histone Modifications and Activates ALDH1A1 to Drive Renal Cell Carcinoma.
Schoenfeld DA; Zhou R; Zairis S; Su W; Steinbach N; Mathur D; Bansal A; Zachem AL; Tavarez B; Hasson D; Bernstein E; Rabadan R; Parsons R
Mol Cancer Res; 2022 Aug; 20(8):1193-1207. PubMed ID: 35412614
[TBL] [Abstract][Full Text] [Related]
24. Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy.
Bai F; Niu Z; Tian H; Li S; Lv Z; Zhang T; Ren G; Li D
Immunol Lett; 2014; 159(1-2):36-46. PubMed ID: 24613899
[TBL] [Abstract][Full Text] [Related]
25. Targeting
Le PT; Ha N; Tran NK; Newman AG; Esselen KM; Dalrymple JL; Schmelz EM; Bhandoola A; Xue HH; Singh PB; Thai TH
Front Immunol; 2021; 12():738958. PubMed ID: 34721405
[TBL] [Abstract][Full Text] [Related]
26. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
[TBL] [Abstract][Full Text] [Related]
27. Anti-PD1 antibody enhances the anti-tumor efficacy of MUC1-MBP fusion protein vaccine via increasing Th1, Tc1 activity and decreasing the proportion of MDSC in the B16-MUC1 melanoma mouse model.
Zhang Z; Zhou H; Liu Y; Ren J; Wang J; Sang Q; Lan Y; Wu Y; Yuan H; Ni W; Tai G
Int Immunopharmacol; 2021 Dec; 101(Pt A):108173. PubMed ID: 34607233
[TBL] [Abstract][Full Text] [Related]
28. The chromatin-remodeling subunit Baf200 promotes homology-directed DNA repair and regulates distinct chromatin-remodeling complexes.
de Castro RO; Previato L; Goitea V; Felberg A; Guiraldelli MF; Filiberti A; Pezza RJ
J Biol Chem; 2017 May; 292(20):8459-8471. PubMed ID: 28381560
[TBL] [Abstract][Full Text] [Related]
29. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.
Yang R; Sun L; Li CF; Wang YH; Yao J; Li H; Yan M; Chang WC; Hsu JM; Cha JH; Hsu JL; Chou CW; Sun X; Deng Y; Chou CK; Yu D; Hung MC
Nat Commun; 2021 Feb; 12(1):832. PubMed ID: 33547304
[TBL] [Abstract][Full Text] [Related]
30. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
31. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L).
Winter H; Hu HM; Urba WJ; Fox BA
J Immunol; 1999 Oct; 163(8):4462-72. PubMed ID: 10510388
[TBL] [Abstract][Full Text] [Related]
32. PBAF chromatin remodeler complexes that mediate meiotic transitions in mouse.
de Castro RO; Previato de Almeida L; Carbajal A; Gryniuk I; Pezza RJ
Development; 2022 Sep; 149(18):. PubMed ID: 36111709
[TBL] [Abstract][Full Text] [Related]
33. miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8
Ji Y; Fioravanti J; Zhu W; Wang H; Wu T; Hu J; Lacey NE; Gautam S; Le Gall JB; Yang X; Hocker JD; Escobar TM; He S; Dell'Orso S; Hawk NV; Kapoor V; Telford WG; Di Croce L; Muljo SA; Zhang Y; Sartorelli V; Gattinoni L
Nat Commun; 2019 May; 10(1):2157. PubMed ID: 31089138
[TBL] [Abstract][Full Text] [Related]
34. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
35. Murine B16 melanomas expressing high levels of the chemokine stromal-derived factor-1/CXCL12 induce tumor-specific T cell chemorepulsion and escape from immune control.
Vianello F; Papeta N; Chen T; Kraft P; White N; Hart WK; Kircher MF; Swart E; Rhee S; Palù G; Irimia D; Toner M; Weissleder R; Poznansky MC
J Immunol; 2006 Mar; 176(5):2902-14. PubMed ID: 16493048
[TBL] [Abstract][Full Text] [Related]
36. MUC1-C Dictates PBRM1-Mediated Chronic Induction of Interferon Signaling, DNA Damage Resistance, and Immunosuppression in Triple-Negative Breast Cancer.
Yamashita N; Morimoto Y; Fushimi A; Ahmad R; Bhattacharya A; Daimon T; Haratake N; Inoue Y; Ishikawa S; Yamamoto M; Hata T; Akiyoshi S; Hu Q; Liu T; Withers H; Liu S; Shapiro GI; Yoshizumi T; Long MD; Kufe D
Mol Cancer Res; 2023 Mar; 21(3):274-289. PubMed ID: 36445328
[TBL] [Abstract][Full Text] [Related]
37. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
38. CTL-dependent and -independent antitumor immunity is determined by the tumor not the vaccine.
Leitch J; Fraser K; Lane C; Putzu K; Adema GJ; Zhang QJ; Jefferies WA; Bramson JL; Wan Y
J Immunol; 2004 May; 172(9):5200-5. PubMed ID: 15100257
[TBL] [Abstract][Full Text] [Related]
39. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells.
Cueto FJ; Del Fresno C; Brandi P; Combes AJ; Hernández-García E; Sánchez-Paulete AR; Enamorado M; Bromley CP; Gomez MJ; Conde-Garrosa R; Mañes S; Zelenay S; Melero I; Iborra S; Krummel MF; Sancho D
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33980589
[TBL] [Abstract][Full Text] [Related]
40. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
Hou J; Wang Y; Shi L; Chen Y; Xu C; Saeedi A; Pan K; Bohat R; Egan NA; McKenzie JA; Mbofung RM; Williams LJ; Yang Z; Sun M; Liang X; Rodon Ahnert J; Varadarajan N; Yee C; Chen Y; Hwu P; Peng W
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
